Merck invests $110 million to expand production site in China
Company will expand the existing production site in Wuxi to significantly increase biopharma single-use assemblies and custom design capabilities
Company will expand the existing production site in Wuxi to significantly increase biopharma single-use assemblies and custom design capabilities
Blood test for early detection of Alzheimer's Disease (AD) risk will lead to better patient care, physicians say; US. adults call for earlier evaluation and more education
The planned Phase 1 study is a double-blind, randomized, placebo-controlled dose-escalation study in healthy adult subjects and AD patients
Biocon Biologics’ Insugen formulations will be available to patients at all Ministry of Health hospitals, district health offices and health clinics
Pre-exposure prevention trial reduced risk of symptomatic Covid-19, with no severe disease or Covid-19-related deaths in the Evusheld group
Support for biologics manufacturability and Industry 4.0 initiatives
In this role, Romanelli will have P&L responsibility for Merck’s US $22 billion international human health business and lead a team of 14,000 colleagues in more than 75 markets outside of the U.S
Bionova Scientific’s process development capabilities are particularly highly regarded in the industry, and it has a rich track record regarding complex next-generation antibody drugs, which are typically challenging to manufacture
This marks an expansion of the companies' existing collaboration and further validates the use of Albumedix Recombumin rHA products in the manufacturing process and final formulation of critical vaccines
Marks the second of three biosimilars Amneal expects to receive U.S. approval for in 2022
Subscribe To Our Newsletter & Stay Updated